Botulinum toxin for treating shoulder pain from degenerative rotator cuff disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of botulinum toxin (incobotulinumtoxinA) in alleviating persistent shoulder pain caused by degenerative rotator cuff disease. The research focuses on patients over 40 years old who have experienced significant pain for more than a month and have ultrasound-confirmed tendinopathy. Participants will receive either the botulinum toxin or a placebo, and their pain levels and functional outcomes will be monitored throughout the study. The hypothesis is that botulinum toxin may reduce mechanical stress on the affected tendon, potentially preventing further damage and pain.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age \> 40 years;
* pain duration \> 1 month;
* pain intensity ≥ 40/100 on visual analog scale;
* SPADI ≥ 30/100;
* medication against pain stable at least 30 days before enrolment;
* pain with or without weakness during the Jobe manoeuver;
* ultrasonography within the 30 days, showing tendinopathy of the supra-spinatus, with or without tear;
* affiliation to health insurance Sécurité Sociale;
* ability to give consent, complete the weekly notebook (collection of drug treatments taken against pain);
* availability for the visits planned by the protocol;
* use of an effective method of contraception in women of childbearing potential, started at least 1 month before and lasting for at least 1 month after receiving study treatment.
* Negative urine test for women of childbearing age

Exclusion Criteria:

* reduced passive range of motion;
* antero-posterior instability;
* tendinous calcification;
* ultrasonography showing concomitant tear of the infra-spinatus or the subscapularis;
* corticosteroid injection within the previous 30 days;
* previous surgery of the shoulder;
* humeral fracture, inflammatory joint disease and neoplastic disorders;
* contraindication to XEOMIN® (allergy to XEOMIN® or any other botulinum toxin product);
* skin infection at the planned injection site;
* participation in another interventional research involving the human person (RIPH) during the 3 months of follow-up of the DEROTOX Research; participation in another RIPH will be possible beyond these 3 months;
* concomitant use of aminoglycosides, cyclosporine, aminoquinolines and spectinomycine;
* patients with a history of aspiration pneumonia and dysphagia;
* patients on anticoagulant therapy or on therapy that may have an anticoagulant effect;
* Patients with bleeding disorders;
* Patients with amyotrophic lateral sclerosis, myasthenia gravis or, Lambert-Eaton syndrome;
* Patients with other conditions causing peripheral neuromuscular dysfunction;
* In target muscles that show pronounced weakness or atrophy;
* Women of childbearing age who have not performed a urine pregnancy test and or who have a positive urine pregnancy test;
* in case of pregnancy, breastfeeding
* injection of botulinum toxin in the last 6 months
* vulnerable people (under legal protection, guardianship or curatorship)

Where it's running

• Hôpital LARIBOISIERE
  Paris, Paris, France Recruiting

Study contacts

• Principal investigator: Johann MD BEAUDREUIL, PHD — Hôpital Lariboisière Fernand Widal
• Study coordinator: Johann MD BEAUDREUIL, PHD
• Email: johann.beaudreuil@aphp.fr
• Phone: +33(0) 1 49 95 63 08

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Functional electrical stimulation plus shoulder exercises for older adults with rotator cuff pain

  In older adults with rotator cuff–related shoulder pain, this study tests whether adding functional electrical stimulation to a shoulder exercise program improves muscle coordination and reduces impingement compared with exercises alone.

  Recruiting University of Texas at Austin · Austin, Texas · NCT07886827

• Long-Term Safety and Efficacy of Allogenic Umbilical Cord–Derived MSCs for Rotator Cuff Disease

  This long-term follow-up checks whether allogenic umbilical cord–derived mesenchymal stem cells are safe and helpful for people with rotator cuff disease who previously received the treatment.

  Recruiting Seoul National University Hospital · Seoul, Korea · NCT07374679

• Using stem cells to repair large rotator cuff tears

  This study is testing whether injections of stem cells from umbilical cords can help people with large rotator cuff tears recover better after surgery.

  Recruiting Korea University Anam Hospital · Seoul, Korea · NCT06817616

• Using stem cells from umbilical cords to treat rotator cuff disease

  This study is testing if injections of stem cells from umbilical cords can help people with rotator cuff disease who haven't found relief from other treatments.

  Recruiting Phase 1/2 Seoul National University Hospital · Seoul, Korea · NCT06794294

• Understanding the significance of rotator cuff disease

  This study is trying to learn more about how rotator cuff disease affects patients by using shoulder questionnaires and exercise to see what improvements matter most to them.

  Recruiting Kırklareli University · Kırklareli · NCT06677320

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.